Autonomix Medical

Autonomix Medical, Inc. is a United States-based medical device company focused on precision nerve-targeted therapies for diseases of the peripheral nervous system. According to its official materials, the company is developing what it describes as the world's first 'GPS for the nervous system': a first-in-class platform technology that introduces real-time, intra-procedural nerve mapping. The goal is to create a new paradigm in therapeutic electrophysiology by enabling physicians to sense nerve activity, guide treatment with greater precision, and verify that treatment has worked — an approach the company frames as a groundbreaking advancement in transvascular denervation. The core of the platform is a proprietary, catheter-based microchip sensing array. Autonomix states that this sensing technology combines ultra-high sensitivity with data processing performed directly at the point of sensing, allowing it to detect and differentiate neural signals. The company reports that its custom-designed sensing antenna array has achieved detection thresholds below 5 µV using prototype electrodes as small as 0.02 mm x 0.03 mm, and that it has compressed lab-grade sensing and processing electronics into a 1×2 mm microchip positioned just millimeters from the targeted nerve. This is intended to overcome the limitations of conventional nerve-sensing technologies, which the company says rely on sending faint electrical signals through wires to external, room-sized processors and often lose critical data along the way. The therapeutic side of the platform uses a minimally invasive, transvascular approach. By accessing key organs and nerves through the vascular system — which the company calls the 'vascular highway' — Autonomix aims to deliver targeted radiofrequency (RF) ablation through the vessel wall. In its intended workflow, the system senses nerve activity, treats by ablating the responsible overactive nerves, and then verifies that signaling has stopped. The company positions this single platform as potentially applicable across a range of disease categories, including hypertension, chronic pain, cardiology, interventional pain management, pulmonology, and gastroenterology. Autonomix describes its mission as dramatically improving the quality of millions of lives by empowering the nerve-targeted treatments of tomorrow and equipping physicians with tools for unparalleled precision in diagnosis and treatment. The company says it is protected by exclusive rights to a rapidly growing global intellectual property portfolio that includes 18 patent families and more than 120 issued or pending applications worldwide. Public records associate the company with Doylestown, Pennsylvania, in the United States. Its official web presence is autonomix.com.

Autonomix Medical, Inc. is a medical device company associated with Doylestown, Pennsylvania, in the United States. Public records identify it as a company in Doylestown, and its official website presents it as a developer of precision nerve-targeted therapies for peripheral nervous system diseases. The available evidence does not specify a founding year, founders, or a detailed corporate chronology, so the following account is based on the company's own description of its mission, technology, and intended clinical applications. The company's stated mission is to dramatically improve the quality of millions of lives by empowering the nerve-targeted treatments of tomorrow, and to equip physicians with innovative tools that allow for unparalleled precision in diagnosis and treatment. Autonomix frames its work around a single, first-in-class platform technology that it says introduces real-time, intra-procedural nerve mapping — described in its materials as the world's first 'GPS for the nervous system.' The company positions this as a potential new paradigm in therapeutic electrophysiology, enabling physicians to sense nerve activity and guide treatment precision, which it characterizes as a groundbreaking advancement in the field of transvascular denervation. The technological foundation described by Autonomix is a proprietary, catheter-based microchip sensing array. According to the company, this sensing technology enables the detection and differentiation of neural signals by combining ultra-high sensitivity with data processing performed directly at the sensing site. Autonomix states that its custom-designed sensing antenna array has achieved detection thresholds below 5 µV using prototype electrodes as small as 0.02 mm x 0.03 mm, capturing both high-fidelity signal resolution and spatial precision. The company further states that it has miniaturized lab-grade processing by compressing an entire lab into a 1×2 mm microchip with embedded sensing and processing electronics, positioned just millimeters from the targeted nerve. This design is presented as a departure from conventional nerve-sensing technologies that rely on sending faint electrical signals through wires to external, room-sized processors and that, in the company's account, often lose critical data along the way. The therapeutic approach built on this sensing capability is minimally invasive and transvascular. Autonomix describes using internal access to key organs and nerves through the vascular system — which it calls the 'vascular highway' — to deliver targeted ablation transvascularly through the vessel wall. In the company's described workflow, the system senses nerve activity, uses radiofrequency (RF) ablation to disable the responsible nerves, and then verifies that signaling has stopped. Autonomix presents this sense-treat-verify sequence as the basis for a single platform that could open up transformative denervation treatment across a number of disease categories, including hypertension, chronic pain, cardiology, pulmonology, and gastroenterology, as well as interventional pain management. Autonomix states that it is protected by exclusive rights to a rapidly growing global intellectual property portfolio, including 18 patent families and more than 120 issued or pending applications worldwide. The company describes itself as building a category-defining solution with the potential to unlock new treatments across cardiology, interventional pain management, pulmonology, gastroenterology, and more. Its first-in-class system is described as allowing internal access to key organs and nerves through the vascular system, with the aim of enabling physicians to sense, treat, and verify. The available evidence does not include dated milestones such as regulatory clearances, clinical trial results, financing events, or public listings, and no such events are asserted here.

Developer of a first-in-class, minimally invasive transvascular nerve sensing and ablation platform intended to set a new standard in neural signal detection and precision denervation across multiple disease categories.

• Catheter-based microchip sensing array

  A proprietary sensing array that combines ultra-high sensitivity with data processing performed directly at the sensing site, intended to detect and differentiate neural signals. The company reports detection thresholds below 5 µV using prototype electrodes as small as 0.02 mm x 0.03 mm.

• 1×2 mm sensing and processing microchip

  A miniaturized chip with embedded sensing and processing electronics, positioned just millimeters from the targeted nerve, described as compressing an entire lab into a 1×2 mm form factor.

• Transvascular radiofrequency (RF) ablation system

  A minimally invasive system that delivers targeted ablation transvascularly through the vessel wall to disable responsible nerves, followed by verification that signaling has stopped.

1. 1Autonomix – Breakthrough Technology for the Nervous Systemautonomix.com
2. 2About – Autonomixautonomix.com
3. 3Technology – Autonomixautonomix.com
4. 4Autonomix Medical (United States) – Wikidatawikidata.org